Cite
HARVARD Citation
Visvanathan, K. et al. (2016). Toll‐IL1 receptor‐mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated‐IFN in HBeAg‐positive CHB patients. Journal of viral hepatitis. 23 (3), pp. 170-179. [Online].